| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/07/2023 | 117.16% | HC Wainwright & Co. | → $20 | Reiterates | Buy → Buy |
| 07/06/2023 | 8.58% | Morgan Stanley | $13 → $10 | Maintains | Equal-Weight |
| 06/29/2023 | 106.3% | Goldman Sachs | $21 → $19 | Maintains | Buy |
| 06/28/2023 | 117.16% | HC Wainwright & Co. | $20 → $20 | Reiterates | Buy → Buy |
| 06/08/2023 | 117.16% | HC Wainwright & Co. | → $20 | Reiterates | Buy → Buy |
| 05/09/2023 | 52.01% | Wedbush | $15 → $14 | Maintains | Outperform |
| 05/09/2023 | 117.16% | HC Wainwright & Co. | $25 → $20 | Maintains | Buy |
| 04/25/2023 | 106.3% | BMO Capital | $20 → $19 | Maintains | Outperform |
| 04/25/2023 | 62.87% | Wedbush | $20 → $15 | Maintains | Outperform |
| 03/28/2023 | 8.58% | B of A Securities | → $10 | Initiates Coverage On | → Buy |
| 03/10/2023 | 171.44% | HC Wainwright & Co. | → $25 | Reiterates | → Buy |
| 03/10/2023 | 117.16% | Wedbush | $25 → $20 | Maintains | Outperform |
| 01/05/2023 | 117.16% | BMO Capital | → $20 | Initiates Coverage On | → Outperform |
| 11/21/2022 | 52.01% | Morgan Stanley | $15 → $14 | Maintains | Equal-Weight |
| 08/24/2022 | 62.87% | Morgan Stanley | $25 → $15 | Downgrades | Overweight → Equal-Weight |
| 08/10/2022 | 171.44% | HC Wainwright & Co. | $18 → $25 | Maintains | Buy |
| 05/24/2022 | 128.01% | Goldman Sachs | $30 → $21 | Maintains | Buy |
| 05/23/2022 | 171.44% | Morgan Stanley | $26 → $25 | Maintains | Overweight |
| 05/20/2022 | 95.44% | HC Wainwright & Co. | $25 → $18 | Maintains | Buy |
| 12/15/2021 | 182.3% | Morgan Stanley | $23 → $26 | Maintains | Overweight |
| 11/22/2021 | 171.44% | HC Wainwright & Co. | → $25 | Initiates Coverage On | → Buy |
| 03/23/2021 | 149.73% | Morgan Stanley | $24 → $23 | Maintains | Overweight |
| 11/17/2020 | 160.59% | Wedbush | → $24 | Initiates Coverage On | → Outperform |
| 11/17/2020 | 160.59% | Morgan Stanley | → $24 | Initiates Coverage On | → Overweight |
| 11/17/2020 | 193.16% | Goldman Sachs | → $27 | Initiates Coverage On | → Buy |
| 11/17/2020 | — | Cowen & Co. | Initiates Coverage On | → Outperform |
What is the target price for Foghorn Therapeutics (FHTX)?
The latest price target for Foghorn Therapeutics (NASDAQ: FHTX) was reported by HC Wainwright & Co. on August 7, 2023. The analyst firm set a price target for $20.00 expecting FHTX to rise to within 12 months (a possible 117.16% upside). 16 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Foghorn Therapeutics (FHTX)?
The latest analyst rating for Foghorn Therapeutics (NASDAQ: FHTX) was provided by HC Wainwright & Co., and Foghorn Therapeutics reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Foghorn Therapeutics (FHTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Foghorn Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Foghorn Therapeutics was filed on August 7, 2023 so you should expect the next rating to be made available sometime around August 7, 2024.
Is the Analyst Rating Foghorn Therapeutics (FHTX) correct?
While ratings are subjective and will change, the latest Foghorn Therapeutics (FHTX) rating was a reiterated with a price target of $0.00 to $20.00. The current price Foghorn Therapeutics (FHTX) is trading at is $9.21, which is within the analyst's predicted range.